All In Biotech

Drug Trial Radar · NCT01682083

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 870 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

870

Actual

Start

Jan 8, 2013

Primary completion

Jun 30, 2017

Study completion Jul 31, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 10, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus 2 placebos in the adjuvant treatment of melanoma after surgical resection. Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk (Stage IIIa \[lymph node metastasis \>1 mm\], IIIb or IIIc) cutaneous melanoma were screened for eligibility. Approximately 852 patients were planned to be randomized in a 1:1 ratio, stratified by BRAF mutation status (V600E, V600K) and stage of disease (Stage IIIa, IIIb, IIIc). Patients received either dabrafenib (150 milligram (mg) twice daily \[BID\]) and trametinib (2 mg once daily \[QD\]) combination therapy or 2 matching placebos (one each for dabrafenib and trametinib) for 12 months or until disease recurrence, death, unacceptable toxicity, or withdrawal of consent. Patients were followed for disease recurrence and survival during and after the treatment period. The study did not permit crossover. Doses of study treatment could be modified and/or interrupted for management of toxicities associated with study treatment.

Conditions

  • Melanoma

Interventions

  • DabrafenibDrug

    Each capsule contained 50 mg or 75 mg of free base (present as the mesylate salt)

  • TrametinibDrug

    Each tablet contained 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)

  • PlacebosDrug

    The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Relapse-free Survival (RFS) EventsTime frame: Approximately 4 years
  2. Relapse-free Survival (RFS)Time frame: Approximately 4 years

Locations

168 sites in 25 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    Aurora, Colorado

  • Novartis Investigative Site

    Lake Worth, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Lutherville-Timonium, Maryland

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Ann Arbor, Michigan

  • Novartis Investigative Site

    Winston-Salem, North Carolina

  • Novartis Investigative Site

    Columbus, Ohio

  • Novartis Investigative Site

    Portland, Oregon

  • Novartis Investigative Site

    Pittsburgh, Pennsylvania

  • Novartis Investigative Site

    Nashville, Tennessee

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Capital Federal, Buenos Aires, Argentina

  • Novartis Investigative Site

    Gateshead, New South Wales, Australia

  • Novartis Investigative Site

    North Sydney, New South Wales, Australia

  • Novartis Investigative Site

    Tweed Heads, New South Wales, Australia

  • Novartis Investigative Site

    Westmead, New South Wales, Australia

  • Novartis Investigative Site

    Greenslopes, Queensland, Australia

  • Novartis Investigative Site

    Woolloongabba, Queensland, Australia

  • Novartis Investigative Site

    Adelaide, South Australia, Australia

  • Novartis Investigative Site

    Box Hill, Victoria, Australia

  • Novartis Investigative Site

    Heidelberg, Victoria, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Salzburg, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Wels, Austria

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

Showing 40 of 168 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.